HIV-1 subtype B protease and reverse transcriptase amino acid covariation
about
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceViral population estimation using pyrosequencingCorrelated electrostatic mutations provide a reservoir of stability in HIV proteaseIntegrated analysis of residue coevolution and protein structures capture key protein sectors in HIV-1 proteinsDeep sequencing of protease inhibitor resistant HIV patient isolates reveals patterns of correlated mutations in Gag and proteaseA Functional Interplay between Human Immunodeficiency Virus Type 1 Protease Residues 77 and 93 Involved in Differential Regulation of Precursor Autoprocessing and Mature Protease ActivityPrediction of mutational tolerance in HIV-1 protease and reverse transcriptase using flexible backbone protein designHIV-1 drug resistance and resistance testing.Emerging Computational Methods for the Rational Discovery of Allosteric Drugs.CoVaMa: Co-Variation Mapper for disequilibrium analysis of mutant loci in viral populations using next-generation sequence data.An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope.Theme and variations in the evolutionary pathways to virulence of an RNA plant virus species.Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapyPairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease.Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1.Inference of Epistatic Effects Leading to Entrenchment and Drug Resistance in HIV-1 Protease.A bioinformatics pipeline for the analyses of viral escape dynamics and host immune responses during an infectionConstrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Inferring viral quasispecies spectra from 454 pyrosequencing reads.A multifaceted analysis of HIV-1 protease multidrug resistance phenotypesHIV-1 antiretroviral resistance: scientific principles and clinical applicationsA Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.HIV-1 transmitted drug resistance-associated mutations and mutation co-variation in HIV-1 treatment-naïve MSM from 2011 to 2013 in Beijing, China.Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potencyDirected evolution of the substrate specificity of biotin ligase.A new ensemble coevolution system for detecting HIV-1 protein coevolution.Impaired infectivity of ritonavir-resistant HIV is rescued by heat shock protein 90AB1.Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.ViQuaS: an improved reconstruction pipeline for viral quasispecies spectra generated by next-generation sequencing.Vaccine preventability of meningococcal clone, Greater Aachen Region, Germany.Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in ChinaMapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients.Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudineHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTAnalysis of coevolution in nonstructural proteins of chikungunya virus.New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitorsFive-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens.Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
P2860
Q28471689-664AA54A-80AB-4397-9E61-550586C8229FQ28472641-ED30B01E-2B89-4932-9193-8CFD73BC54A5Q28483556-C7995743-DC6F-4ED3-A226-51AA0A47336AQ28543396-0DBD781A-CEC0-47C3-BFEF-5D1A625C9C8AQ28546549-9C95C74D-D9BF-429B-A200-141FCCA826A5Q28546560-40BFC484-7585-4349-A04A-B651692E716EQ28914732-59299B13-949E-4C2D-BC8E-9174F0AEC681Q30245693-4150E216-5410-4A15-BC74-9B8C1FF36A39Q30358225-895E057C-B1D5-4298-BA3A-766A7FDEC28AQ30997587-F084EB64-9169-40B6-99E0-7A9A472007B1Q33307183-EFF9074B-2137-4984-8FD2-41B56A990460Q33307185-D9F169B5-EDC6-4569-9998-DDC127FED22CQ33378828-3B1E11F7-4AD6-4534-A7B0-599D70B02578Q33503921-91222E41-384A-429B-BD39-0F0C5981DAAFQ33517082-6C3BA0B3-8A60-48BA-9DF5-0CE857EF2CA8Q33698683-758F9751-1163-41AA-BBAB-238F58CEB7E5Q33810826-C57955C3-8369-40B5-B12F-1DA7F5D99631Q33902540-7A0AD5A3-1453-49B8-B58E-1F2A41C81394Q34046595-E0082CBC-C4BC-4F8F-8906-5BAC79452632Q34102058-DD891D3E-6CCF-417C-ADCA-BAF4226124ECQ34280466-F3959FB8-EE2D-4AE0-9210-87C8EAA38CA6Q34573897-8F8D024C-374E-45BE-AFFC-00EFEE3A7918Q34740512-C25AAA8D-6F4E-4F64-A028-A34FFE82372EQ35001188-D01061DB-2EF5-4B27-B11D-916DCFE26B09Q35077297-958D9762-4D88-4232-974F-5AD03B5D4EABQ35094794-F5CE0A81-ED48-4172-8A4C-DEF6CAB49D9BQ35107346-FC010364-61B6-4A52-A17B-FBFB071E3254Q35120811-1C12B309-A705-48BA-867F-000DE0AD0ECEQ35422196-F9341F67-41DF-47B4-8D86-ACF430B50108Q35877401-C286F29A-11C2-4BCB-8417-9763434AE569Q36252846-797013BC-9830-4757-B253-2B39ABF8C8EBQ36315090-7DF5BA61-2F76-407B-AAD1-E75DEF973319Q36505336-BC86BD62-7F89-4363-A1E3-79337C208FFFQ36852626-A5AAF3B4-A5CE-4F71-8898-368016B061EDQ36900010-59104E3D-E32C-4ADA-81BE-2C755FA2873FQ36960778-9F00C299-D66D-45FF-99EC-F59FAE030C90Q37262113-2D5F5FCB-70BD-40A2-ADAC-1C6EFD5F0078Q37405816-BD1B782F-5593-4A2D-9D57-7BABD7C5BCEAQ37432131-3D875480-9A62-4F8E-AF62-28F52F881512Q39621109-19BC50D7-A1F4-45BE-9E95-D651F1C4BC50
P2860
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
@ast
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
@en
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
@nl
type
label
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
@ast
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
@en
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
@nl
prefLabel
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
@ast
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
@en
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
@nl
P2093
P2860
P3181
P1476
HIV-1 subtype B protease and reverse transcriptase amino acid covariation
@en
P2093
Robert W Shafer
Soo-Yon Rhee
Tommy F Liu
P2860
P3181
P356
10.1371/JOURNAL.PCBI.0030087
P407
P50
P577
2007-05-01T00:00:00Z